Daniel Moon

Daniel Duk-ki Moon

Associate
Baker & McKenzie LLP
Admitted only in New York. Practice supervised by members of the DC Bar.

Biography

Daniel Duk-ki (pronounced “duck key”) Moon serves as a trusted advisor to U.S. and international clients in all phases of U.S. and multijurisdictional merger review processes and advises on a broad range of antitrust and regulatory issues related to both domestic and cross border mergers and acquisitions, joint ventures, and other business arrangements, including notifications and clearances under the Hart-Scott-Rodino Act. He also counsels clients on compliance and enforcement issues related to cartels, vertical restraints, market manipulation, hub-and-spoke liability, and other antitrust law matters.

With a reputation for delivering practical, business-oriented solutions, Duk-ki leverages his experience working on bet-the-company mergers and managing multijurisdictional remedies negotiations to strike the balance between managing regulatory demands all while prioritizing the client’s commercial drivers.

Practice Focus

Duk-ki has particular expertise in the pharmaceuticals industry and has helped leading multinational companies with various transactions and antitrust matters but also has strong credentials across a wide variety of industries, such as health insurance, heavy machinery, mining, oil and gas, healthcare, technology, chemicals, mining, technology, fintech, and agriculture.

Representative Legal Matters

Duk-ki has advised clients on a wide range of antitrust matters (both prior to and at Baker McKenzie), including:

  • Owens Corning on its approximately USD 755 million global divestiture of its glass reinforcement business to Praana Group
  • Lyft on its EUR 175 million acquisition of Freenow
  • H. Lundbeck A/S on its approximately USD 2.5 billion acquisition of Longboard Pharmaceuticals
  • Bayer AG on its approximately USD 2 billion acquisition of Vividion Therapeutics, Inc.
  • Numab Therapeutics on its approximately USD 1.25 billion sale of Yellow Jersey Therapeutics
  • Galapagos NV on its approximately USD 5.1 billion collaboration with Gilead Sciences Inc.
  • Bayer AG on its approximately USD 4 billion acquisition of Asklepios BioPharmaceutical, Inc.
  • The Nielsen Company on its approximately USD 2.7 billion sale of Nielsen IǪ to Advent International
  • ALDI in its acquisition of Southeastern Grocers, including the Winn-Dixie and Harveys Supermarket brands
  • Sika AG on its approximately USD 6 billion acquisition of MBCC Group
  • Novartis on various antitrust matters, including its series of transactions with GlaxoSmithKline 
  • Western Refining, Inc. on its acquisition by Tesoro Corporation before the Federal Trade Commission
  • Wellpoint (now Anthem) on various antitrust matters, including its acquisition of Amerigroup
  • Glencore plc on its merger with Xstrata before the DOJ
  • Actavis Group on its EUR 4.25 billion sale to Watson Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company on various antitrust matters, including its USD 62 billion acquisition of Shire plc

Professional Honors

  • Future Leader, Lexology Competition Index (formerly Who’s Who Legal) (2023, 2024, 2025)

Professional Associations and Memberships

  • American Bar Association - Member, Antitrust section
  • National Asian Pacific American Bar Association - Member
  • Asian Pacific American Bar Association, DC - Member

Admissions

  • New York~United States (2013)

Education

  • Yeshiva University (JD) (2011)
  • Berklee College of Music (BA) (2007)

Languages

  • English
  • Korean
  • Associate Editor, Health Care Chronicle, Health Care and Pharmaceuticals Committee
  • Regular contributor, Recent Developments Newsletter, Health Care and Pharmaceuticals Committee
  • "Market Definition for Innovative Pharmaceuticals: How Far Should We Go?," Antitrust Health Care Chronicle, October 2019
  • Who's Afraid of "Killer Acquisitions?,” ABA Newsletter of the Mergers & Acquisitions Committee, Summer 2019
  • Co-author, “Cooperation or Compliance? In re Aftermarket Automotive Lighting and the Denial of ACPERA Protection for Unsatisfactory Cooperation,” Cartel & Criminal Practice Committee Newsletter, Spring 2014